TrialLancet (London, England)2018

Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.

Joshua D Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.